Oliver Sexton: Investment Director

Oliver Sexton

Oliver Sexton joined Midven in April 2014 to manage the Rainbow Seed Fund’s synthetic biology investments.

Prior to joining Midven, Oliver managed commercialisation of bioengineering and medical technologies At Imperial Innovations and was on the board of oncology therapeutic Acublate Ltd. Earlier in his career he held commercial and partnering roles at Ark Therapeutics.

Oliver also managed a team of biotech buy-side analysts and worked at a pharma strategy consultancy.

Oliver has a BSc in Molecular Biology/Biotechnology and an MSc in Plant Science from Bristol University.

Telephone 0121 710 1990

“Turning world-leading research into profitable companies is no simple matter, but we are now at a point where many of those technologies are suitable for broad commercial application. Rainbow Seed Fund is providing not just capital, but the expertise and the networks to maximize the chances of success in existing markets and in the new markets that synthetic biology enables.”

Oliver Sexton

Associated Companies

Relevant News

Rainbow Seed Fund & University of Birmingham Back Promising Technology Spinout Linear Diagnostics

Spinout developing novel hand-held reader to help in the fight against antibiotic resistance 24 May…

read more

Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes

Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed…

read more

Cytox Plans US Clinical Launch for Early-Stage Alzheimer's Test While Courting Pharma Partners

  May 03, 2017 Justin Petrone www.genomeweb.com British molecular diagnostics company Cytox plans to make…

read more

Gene Therapy Company Quethera Obtains Grant From Wellcome Trust Pathfinder Award Scheme

Quethera Ltd, a privately funded gene therapy company based at the Babraham Research Campus in…

read more

Case Studies

Case Study - Synthace

Synthace London-based Synthace provides next-generation software and processes to exponentially improve productivity in bioscience, enabling…

read more

Blog

A Discussion with Rainbow Seed Fund’s Oliver Sexton

Oliver Sexton, MSc, is Midven’s investment director and manager of Rainbow Seed Fund’s synthetic biology…

read more

Today’s Academic Projects Are Becoming Tomorrow’s Billion Pound Companies

  When we talk about the tech revolution that is currently sweeping the industrialised world,…

read more

Other Team Members